529 related articles for article (PubMed ID: 16987658)
1. New rifabutin analogs: synthesis and biological activity against Mycobacterium tuberculosis.
Barluenga J; Aznar F; García AB; Cabal MP; Palacios JJ; Menéndez MA
Bioorg Med Chem Lett; 2006 Nov; 16(22):5717-22. PubMed ID: 16987658
[TBL] [Abstract][Full Text] [Related]
2. In-vitro activity of rifabutin against rifampicin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations.
Cavusoglu C; Karaca-Derici Y; Bilgic A
Clin Microbiol Infect; 2004 Jul; 10(7):662-5. PubMed ID: 15214882
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and evaluation of rifabutin analogs against Mycobacterium avium and H(37)Rv, MDR and NRP Mycobacterium tuberculosis.
Figueiredo R; Moiteiro C; Medeiros MA; da Silva PA; Ramos D; Spies F; Ribeiro MO; Lourenço MC; Júnior IN; Gaspar MM; Cruz ME; Curto MJ; Franzblau SG; Orozco H; Aguilar D; Hernandez-Pando R; Costa MC
Bioorg Med Chem; 2009 Jan; 17(2):503-11. PubMed ID: 19119013
[TBL] [Abstract][Full Text] [Related]
4. [In vitro activities of new rifamycin derivatives against Mycobacterium tuberculosis and M. avium complex].
Yamamoto T; Amitani R; Kuze F; Suzuki K
Kekkaku; 1990 Dec; 65(12):805-10. PubMed ID: 2127615
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of rifabutin and rifampin against clinical isolates of Mycobacterium tuberculosis in Taiwan.
Chien HP; Yu MC; Ong TF; Lin TP; Luh KT
J Formos Med Assoc; 2000 May; 99(5):408-11. PubMed ID: 10870331
[TBL] [Abstract][Full Text] [Related]
6. Activity of KRM 1648 or rifabutin alone or in combination with clarithromycin against Mycobacterium avium complex in human alveolar macrophages.
Suzuki K; Tsuyuguchi K; Matsumoto H; Yamamoto T; Hashimoto T; Tanaka E; Amitani R; Kuze F
Int J Tuberc Lung Dis; 1997 Oct; 1(5):460-7. PubMed ID: 9441102
[TBL] [Abstract][Full Text] [Related]
7. [Study of the minimal inhibitory concentration of rifabutine (Ansamycin LM 427) for Mycobacterium tuberculosis, Mycobacterium xenopi and Mycobacterium avium-intracellulare].
Truffot-Pernot C; Giroir AM; Maury L; Grosset J
Rev Mal Respir; 1988; 5(4):401-6. PubMed ID: 2845531
[TBL] [Abstract][Full Text] [Related]
8. [In vitro activities of benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis].
Sato K; Tomioka H; Saito H; Kawahara S; Hidaka T
Kekkaku; 1996 Aug; 71(8):459-64. PubMed ID: 8831191
[TBL] [Abstract][Full Text] [Related]
9. [Components of monitoring drug resistance of tuberculosis agent in the evaluation of effectiveness of the national tuberculosis control program].
Popov SA; Dorozhkova IR; Medvedeva IM
Probl Tuberk; 2001; (2):18-20. PubMed ID: 11490457
[TBL] [Abstract][Full Text] [Related]
10. [Cross-resistance between rifampin and rifabutin in multidrug resistant Mycobacterium tuberculosis complex strains].
Gao L; Xiao HP; Hu ZY; Cui ZL; Lu JM; Shen XN
Zhonghua Jie He He Hu Xi Za Zhi; 2012 May; 35(5):333-5. PubMed ID: 22883990
[TBL] [Abstract][Full Text] [Related]
11. Strong in vitro activities of two new rifabutin analogs against multidrug-resistant Mycobacterium tuberculosis.
García AB; Palacios JJ; Ruiz MJ; Barluenga J; Aznar F; Cabal MP; García JM; Díaz N
Antimicrob Agents Chemother; 2010 Dec; 54(12):5363-5. PubMed ID: 20855731
[TBL] [Abstract][Full Text] [Related]
12. [In vitro activities of rifabutine and rifampicin against various mycobacteria, especially Mycobacterium tuberculosis and Mycobacterium avium complex].
Saito H; Sato K; Tomioka H
Kekkaku; 1988 Mar; 63(3):167-72. PubMed ID: 2836649
[No Abstract] [Full Text] [Related]
13. Relationship between antimycobacterial activities of rifampicin, rifabutin and KRM-1648 and rpoB mutations of Mycobacterium tuberculosis.
Yang B; Koga H; Ohno H; Ogawa K; Fukuda M; Hirakata Y; Maesaki S; Tomono K; Tashiro T; Kohno S
J Antimicrob Chemother; 1998 Nov; 42(5):621-8. PubMed ID: 9848446
[TBL] [Abstract][Full Text] [Related]
14. Investigation of cross-resistance between rifampin and rifabutin in Mycobacterium tuberculosis complex strains.
Uzun M; Erturan Z; Anğ O
Int J Tuberc Lung Dis; 2002 Feb; 6(2):164-5. PubMed ID: 11931417
[TBL] [Abstract][Full Text] [Related]
15. [In vitro antimicrobial activities of quinolones, rifamycins and macrolides against Mycobacterium tuberculosis and M.avium complex: attempt to establish new assay methods which accurately reflect therapeutic effects of test agents in vivo].
Sato K; Tomioka H
Kekkaku; 1999 Jan; 74(1):63-70. PubMed ID: 10067057
[TBL] [Abstract][Full Text] [Related]
16. [Drug sensitivity in Mycobacterium tuberculosis versus its viability, cytotoxicity, genotype, and the course of the process in patients with pulmonary tuberculosis].
Manicheva OA; Lasunskaia EB; Zhuravlev VIu; Otten TF; Barnaulov AO; Mokrousov IV; Pavlova MV; Vishnevskiĭ BI; Narvskaia OV
Probl Tuberk Bolezn Legk; 2008; (12):18-22. PubMed ID: 19230183
[TBL] [Abstract][Full Text] [Related]
17. Prospects for development of new antimycobacterial drugs, with special reference to a new benzoxazinorifamycin, KRM-1648.
Tomioka H
Arch Immunol Ther Exp (Warsz); 2000; 48(3):183-8. PubMed ID: 10912623
[TBL] [Abstract][Full Text] [Related]
18. Incidence of cross resistance between rifampicin and rifabutin in Mycobacterium tuberculosis strains in Izmir, Turkey.
Senol G; Erbaycu A; Ozsöz A
J Chemother; 2005 Aug; 17(4):380-4. PubMed ID: 16167516
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of a new isothiazoloquinolone, ACH-702, against Mycobacterium tuberculosis and other mycobacteria.
Molina-Torres CA; Ocampo-Candiani J; Rendón A; Pucci MJ; Vera-Cabrera L
Antimicrob Agents Chemother; 2010 May; 54(5):2188-90. PubMed ID: 20231398
[TBL] [Abstract][Full Text] [Related]
20. Anti-tubercular agents. Part 3. Benzothiadiazine as a novel scaffold for anti-Mycobacterium activity.
Kamal A; Reddy KS; Ahmed SK; Khan MN; Sinha RK; Yadav JS; Arora SK
Bioorg Med Chem; 2006 Feb; 14(3):650-8. PubMed ID: 16203154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
